Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA E542K PTEN loss||lung squamous cell carcinoma||sensitive||Alpelisib||Preclinical - Pdx||Actionable||In a preclinical study, Alpelisib (BYL719) treatment resulted in response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PTEN loss (PMID: 30093452).||30093452|
|PIK3CA E542K PTEN loss||breast cancer||predicted - sensitive||CYH33||Preclinical - Cell culture||Actionable||In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K and PTEN loss in culture (PMID: 30003928).||30003928|
|PIK3CA E542K PTEN loss||stomach cancer||unknown||Sirolimus||Phase 0||Actionable||In a pilot clinical trial, Rapamune (sirolimus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).||28685070|
|PIK3CA E542K PTEN loss||breast cancer||sensitive||Taselisib||Preclinical - Cell culture||Actionable||In a preclinical study, a breast cancer cell line harboring PIK3CA E542K was sensitive to treatment with Taselisib (GDC-0032) in culture, demonstrating decreased cell viability (PMID: 31534012).||31534012|
|PIK3CA E542K PTEN loss||breast cancer||predicted - sensitive||Dactolisib + WEHI-539||Preclinical - Cell culture||Actionable||In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).||27974663|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|